These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6419318)

  • 21. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.
    Elhosary MA; Bahey-El-Din M; AbdelBary A; El Guink N; Aboushleib HM
    Microb Pathog; 2019 Jun; 131():181-185. PubMed ID: 30978430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.
    Bruderer U; Cryz SJ; Schaad UB; Deusinger M; Que JU; Lang AB
    J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effector mechanisms of protection against Pseudomonas aeruginosa keratitis in immunized rats.
    Thakur A; Kyd J; Xue M; Willcox MD; Cripps A
    Infect Immun; 2001 May; 69(5):3295-304. PubMed ID: 11292752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccinations against Pseudomonas aeruginosa: active and passive alternatives.
    Bellanti JA; Zeligs BJ; Kulczycki LL
    Pediatr Pulmonol Suppl; 1997; 16():269-70. PubMed ID: 9443307
    [No Abstract]   [Full Text] [Related]  

  • 28. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia.
    Pennington JE; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S852-7. PubMed ID: 6419311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.
    Li Y; Wang Z; Liu X; Tang J; Peng B; Wei Y
    Sci Rep; 2016 Feb; 6():18823. PubMed ID: 26879055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins.
    Sawada S; Suzuki M; Kawamura T; Fujinaga S; Masuho Y; Tomibe K
    J Infect Dis; 1984 Oct; 150(4):570-6. PubMed ID: 6436393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to Pseudomonas aeruginosa. II. Isotype and functional activity of the anti-idiotype-induced antibodies.
    Schreiber JR; Nixon KL; Tosi MF; Pier GB; Patawaran MB
    J Immunol; 1991 Jan; 146(1):188-93. PubMed ID: 1898598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.
    Lieberman MM; Wright GL; Wolcott KM; McKissock-Desoto DC
    Infect Immun; 1980 Aug; 29(2):489-93. PubMed ID: 6783532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice.
    Petit JC; Sicard D; Bayo S; Daguet GL
    Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
    Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
    Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.